Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Carmelo Gurnari,1,2 Ishani Nautiyal,1 Simona Pagliuca1,3 1Department of Translational Hematology and Oncology Research, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology,...
Main Authors: | Gurnari C, Nautiyal I, Pagliuca S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-12-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/current-opinions-on-the-clinical-utility-of-ravulizumab-for-the-treatm-peer-reviewed-fulltext-article-TCRM |
Similar Items
-
Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist’s Opinion
by: Guido Gembillo, et al.
Published: (2020-04-01) -
Efficacy and safety of current treatments for paroxysmal nocturnal hemoglobinuria: A systematic review
by: Yara Maria da Silva Pires, et al.
Published: (2023-12-01) -
Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature
by: Nicole Galli, et al.
Published: (2023-10-01) -
COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab
by: Sufana Shikdar, et al.
Published: (2021-10-01) -
Concept confirmation of the Treatment Administration Satisfaction Questionnaire (TASQ) in rare paroxysmal nocturnal hemoglobinuria
by: Helen Doll, et al.
Published: (2021-06-01)